← All organizations
Highest phase reached
Phase 3
First clinical trial
Feb 1, 1997Last known activity
Jul 25, 2025
Timeline
1980s
- Jan 1, 1986
National Marrow Donor Program— Founded
Drugs by trial phase (53 distinct, 44 trials)
Phase 3 (30 own, 0 via acquisition)
Phase 2 (21 own, 0 via acquisition)
- plerixafor
- idecabtagene vicleucel
- moxetumomab pasudotox
- dendritic cell tumor fusion vaccine
- naltrexone
- bone marrow derived mesenchymal stem cells
- haploidentical mononuclear cells
- hydroxyurea
- ixazomib
- allogeneic hematopoietic stem cells
- abatacept
- bortezomib
- cd33 car-t cells
- cord blood hematopoietic stem cell
- mesna
- +6 more
Phase 1 (1 own, 0 via acquisition)
Other trials (1 own, 0 via acquisition)
Indications
Studied for
- Adenoviridae Infections
- Anemia
- Anemia, Aplastic
- Anemia, Diamond-Blackfan
- Anemia, Sickle Cell
- Burkitt Lymphoma
- Communicable Diseases
- Epstein-Barr Virus Infections
- Graft vs Host Disease
- Granulomatous Disease, Chronic
- Hemoglobinopathies
- Immunologic Deficiency Syndromes
- Infections
- Leukemia
- Leukemia, Biphenotypic, Acute
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Lymphohistiocytosis, Hemophagocytic
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Follicular
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, Mantle-Cell
- Lymphoma, Non-Hodgkin
- Multiple Myeloma
- Mycoses
- Myelodysplastic-Myeloproliferative Diseases
- Myelodysplastic Syndromes
- Myeloproliferative Disorders
- Neoplasm, Residual
- Neoplasms, Plasma Cell
- Neutropenia
- Pneumonia
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Preleukemia
- Syndrome
- Thalassemia
- Tissue Adhesions
- Virus Diseases
Recent trials (49)
- NCT06859424CollaboratorPhase 2Jul 25, 2025
- NCT06001385CollaboratorPhase 2Nov 1, 2023
- NCT05135650CollaboratorPhase 1May 1, 2022
- NCT04965597CollaboratorPhase 2Dec 31, 2021
- NCT04934670CollaboratorPhase 3Dec 1, 2021
- NCT05032820CollaboratorPhase 2Oct 31, 2021
- NCT04975698Study chairPhase 2Oct 25, 2021
- NCT04975698CollaboratorPhase 2Oct 25, 2021
- NCT04904588Overall official - principal investigatorPhase 2Sep 30, 2021
- NCT04904588CollaboratorPhase 2Sep 30, 2021
- NCT04762875Study chairPhase 2Jun 16, 2021
- NCT04762875CollaboratorPhase 2Jun 16, 2021
- NCT03971799CollaboratorPhase 1/Phase 2Oct 31, 2019
- NCT03959241CollaboratorPhase 3Jun 30, 2019
- NCT03263559CollaboratorPhase 2Oct 3, 2017
Details
- Founded
- Minneapolis, MN, US Jan 1, 1986
- Last known activity
- Jul 25, 2025